![Cancers | Free Full-Text | V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma | HTML Cancers | Free Full-Text | V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma | HTML](https://www.mdpi.com/cancers/cancers-13-02219/article_deploy/html/images/cancers-13-02219-g006.png)
Cancers | Free Full-Text | V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma | HTML
![Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review | Future Oncology Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.15.33/asset/images/medium/figure2.gif)
Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review | Future Oncology
![Cancers | Free Full-Text | Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC) | HTML Cancers | Free Full-Text | Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC) | HTML](https://www.mdpi.com/cancers/cancers-11-01297/article_deploy/html/images/cancers-11-01297-g001.png)
Cancers | Free Full-Text | Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC) | HTML
Biohem Lab - ŠTA SU TUMOR MARKERI? Tumor markeri su biološke supstance koje su prisutne u ćelijama, krvi, drugim telesnim tečnostima, kao i tumorskom tkivu osoba obolelih od karcinoma. Dokazivanje ovih supstanci
BioMedica Cazin - TUMORSKI MARKERI Na skali uzroka smrtnosti, tumori zauzimaju, visoko treće mjesto. Kako se još uvijek u velikoj mjeri radi o neizlječivim bolestima, naročito u slučajevima zakašnjele dijagnoze, razumljive su
![Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity | Scientific Reports Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep23820/MediaObjects/41598_2016_Article_BFsrep23820_Fig1_HTML.jpg)
Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity | Scientific Reports
![Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration | BMC Medicine | Full Text Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration | BMC Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1741-7015-10-51/MediaObjects/12916_2011_Article_528_Fig2_HTML.jpg)